Related Experiment Videos
Phase II trial of MVE-II in metastatic malignant melanoma
Cancer Immunology, Immunotherapy : CII
|January 1, 1987
Abstract:
MVE-II, a low molecular weight fraction of pyran copolymer was utilized in a Phase II trial in patients with metastatic malignant melanoma. A total of 15 patients were investigated and no clinical responses or immunologic responses were observed. We concluded that MVE-II is not an active agent in malignant melanoma.